Show simple item record

dc.contributor.authorBecker, Matthias
dc.contributor.authorStrengert, Monika
dc.contributor.authorJunker, Daniel
dc.contributor.authorKaiser, Philipp D
dc.contributor.authorKerrinnes, Tobias
dc.contributor.authorTraenkle, Bjoern
dc.contributor.authorDinter, Heiko
dc.contributor.authorHäring, Julia
dc.contributor.authorGhozzi, Stéphane
dc.contributor.authorZeck, Anne
dc.contributor.authorWeise, Frank
dc.contributor.authorPeter, Andreas
dc.contributor.authorHörber, Sebastian
dc.contributor.authorFink, Simon
dc.contributor.authorRuoff, Felix
dc.contributor.authorDulovic, Alex
dc.contributor.authorBakchoul, Tamam
dc.contributor.authorBaillot, Armin
dc.contributor.authorLohse, Stefan
dc.contributor.authorCornberg, Markus
dc.contributor.authorIllig, Thomas
dc.contributor.authorGottlieb, Jens
dc.contributor.authorSmola, Sigrun
dc.contributor.authorKarch, André
dc.contributor.authorBerger, Klaus
dc.contributor.authorRammensee, Hans-Georg
dc.contributor.authorSchenke-Layland, Katja
dc.contributor.authorNelde, Annika
dc.contributor.authorMärklin, Melanie
dc.contributor.authorHeitmann, Jonas S
dc.contributor.authorWalz, Juliane S
dc.contributor.authorTemplin, Markus
dc.contributor.authorJoos, Thomas O
dc.contributor.authorRothbauer, Ulrich
dc.contributor.authorKrause, Gérard
dc.contributor.authorSchneiderhan-Marra, Nicole
dc.date.accessioned2021-03-25T15:21:07Z
dc.date.available2021-03-25T15:21:07Z
dc.date.issued2021-02-19
dc.identifier.citationNat Commun. 2021 Mar 11;12(1):1577. doi: 10.1038/s41467-021-21609-2.en_US
dc.identifier.pmid33608538
dc.identifier.doi10.1038/s41467-021-20973-3
dc.identifier.urihttp://hdl.handle.net/10033/622797
dc.description.abstractThe humoral immune response to SARS-CoV-2 is a benchmark for immunity and detailed analysis is required to understand the manifestation and progression of COVID-19, monitor seroconversion within the general population, and support vaccine development. The majority of currently available commercial serological assays only quantify the SARS-CoV-2 antibody response against individual antigens, limiting our understanding of the immune response. To overcome this, we have developed a multiplex immunoassay (MultiCoV-Ab) including spike and nucleocapsid proteins of SARS-CoV-2 and the endemic human coronaviruses. Compared to three broadly used commercial in vitro diagnostic tests, our MultiCoV-Ab achieves a higher sensitivity and specificity when analyzing a well-characterized sample set of SARS-CoV-2 infected and uninfected individuals. We find a high response against endemic coronaviruses in our sample set, but no consistent cross-reactive IgG response patterns against SARS-CoV-2. Here we show a robust, high-content-enabled, antigen-saving multiplex assay suited to both monitoring vaccination studies and facilitating epidemiologic screenings for humoral immunity towards pandemic and endemic coronaviruses.en_US
dc.language.isoenen_US
dc.publisherNPGen_US
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/ 101003480en_US
dc.rightsopenAccessen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleExploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity.en_US
dc.typeArticleen_US
dc.identifier.eissn2041-1723
dc.contributor.departmentHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.en_US
dc.identifier.journalNature communicationsen_US
dc.source.volume12
dc.source.issue1
dc.source.beginpage1152
dc.source.endpage
refterms.dateFOA2021-03-25T15:21:08Z
dc.source.journaltitleNature communications
dc.source.countryEngland


Files in this item

Thumbnail
Name:
Becker et al.pdf
Size:
1.893Mb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record

openAccess
Except where otherwise noted, this item's license is described as openAccess